In 2021, Medidata will continue to expand on its growing list of supported devices and sensors that includes BioStamp, ActiGraph, and BioIntellisense. This growing library of high fidelity connected devices in combination with Sensor Cloud's analytics will advance researchers' understanding of disease progression and treatment effects in the home, while enhancing the clinical trial experience for patients. Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.